Physician profile

Omar Samih Qaqish

Cardiovascular Disease · Little Rock, AR

NPI 1578067369

$44,852.68

in general payments reported to CMS, 2019-2025

31 companies · $5,938 in 2025

The $5,938 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Travel and Lodging$21,108.89
Gift$9,360.00
Food and Beverage$8,966.01
Grant$1,063.30
Education$470.70
Consulting Fee$300.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Philips North America LLC $27,598.04 2022-2025 (9520) Igt Devices Undivided, (Bq9) Coronary Ivus, Coronary Other
Abbott Laboratories $5,685.14 2022-2025 Prostar, Gallant, Optis
Inari Medical, INC. $2,854.87 2023-2025 Ct Thrombectomy System Kit, Flowtriever Catheter, S
Boston Scientific Corporation $1,837.16 2022-2024 Lux-Dx Insertable Cardiac Monitor
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $1,468.66 2021-2025 Lifevest
Astrazeneca Pharmaceuticals Lp $877.57 2021-2023 Farxiga
Abiomed $555.41 2022-2024 Impella
Merit Medical Systems INC $509.65 2022
Medtronic, INC. $459.90 2021-2024 Turbohawk, Venaseal, Onyx Frontier
Actelion Pharmaceuticals US, INC. $444.00 2021-2022
Cardiva Medical, INC. $362.62 2024-2025 Cardiva Vascade 6/7f Vcs, Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade Mvp Xl Vvcs 10-12f
Shockwave Medical, INC $282.83 2024-2025 Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter
Penumbra, INC. $264.77 2024 Indigo System
Kestra Medical Technology Services, INC. $231.67 2024-2025 Assure Wcd
Stryker Corporation $226.97 2025 Ct Thrombectomy System Kit, Flowtriever Catheter, S
Show all 31 companies
CompanyGeneral paymentsYearsTop products
Alnylam Pharmaceuticals INC. $219.11 2023 Amvuttra
Teleflex LLC $182.24 2025 Guideliner
Kiniksa Pharmaceuticals International, Plc $145.82 2024 Arcalyst
Janssen Pharmaceuticals, INC $129.09 2022-2024 Xarelto
Angiodynamics, INC. $121.47 2024 Alphavac
Chiesi USA, INC. $89.88 2024-2025 Kengreal, Cleviprex
Cordis US Corp. $62.23 2023-2025 Mynx Control, Mynx Control Venous
Merck Sharp & Dohme LLC $43.88 2022-2023 Verquvo
Pfizer INC. $36.87 2023-2024
Terumo Medical Corporation $34.60 2023-2024 Tr Band, Angio-Seal
Lexicon Pharmaceuticals, INC. $30.36 2023 Inpefa
Boehringer Ingelheim Pharmaceuticals, INC. $26.67 2025 Jardiance
Siemens Medical Solutions USA, INC. $20.97 2022
Novartis Pharmaceuticals Corporation $19.53 2024
Cardiovascular Systems INC. $15.54 2022
Scpharmaceuticals INC. $15.16 2023

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Omar Samih Qaqish

$44,852.68

in general payments reported 2019-2025

Years
2021-2025
Top company
Philips North America LLC
Context
The $5,938 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/9147583/omar-samih-qaqish

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.